KOR
ENG
Company
Greeting
About Us
Overview
Mission & Vision
History
News
Business
Major Business
Product
All-products
Prescription Drugs
Over-the-Counter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Digital Healthcare
Healthcare Products
Partnering
Introduction
Product Licensing
Contract Manufacturing & QC
R&D
Introduction
Pipeline
Sustainability
Overview
Environment
Social
Governance
Governance structure
Ethical Management
Investor
Financial Information
지금 무엇을 찾으시나요?
추천검색어
Prescription Drugs
Over-the-Conunter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Healthcare Products
한독은 인류의 건강과
삶의 질을 위해 노력합니다.
한독과 함께 변화하는 삶
일상건강에서 만나보세요
Company
Greeting
About Us
Overview
Mission & Vision
History
News
Business
Major Business
Product
All-products
Prescription Drugs
Over-the-Counter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Digital Healthcare
Healthcare Products
Partnering
Introduction
Product Licensing
Contract Manufacturing & QC
R&D
Introduction
Pipeline
Sustainability
Overview
Environment
Social
Governance
Governance structure
Ethical Management
Investor
Financial Information
KR
EN
Company
Greeting
About Us
Overview
Mission & Vision
History
News
Business
Major Business
Product
All-products
Prescription Drugs
Over-the-Counter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Digital Healthcare
Healthcare Products
Partnering
Introduction
Product Licensing
Contract Manufacturing & QC
R&D
Introduction
Pipeline
Sustainability
Overview
Environment
Social
Governance
Governance structure
Ethical Management
Investor
Financial Information
궁금한 부분이 있으신가요?
CONTACT
한독과 함께 변화하는 삶
일상건강
모두나롤액
성분
미녹시딜/토코페롤아세테이트/피리독신염산염/L-멘톨
허가변경사항
변경명령(사용상의 주의사항)
변경일
2026.03.10
항목
변경전
변경후
사용상의주의사항
1) ~ 4) <생략
<신설>
5) ~ 12)
<생략>
1) ~ 4) <생략>
5) 미녹시딜을 사용하는 환자(보호자)의 미녹시딜 도포부위와 어린이(영아) 접촉 후 다모증 사례가 보고되므로 어린이와 미녹시딜 도포 부위의 접촉을 피해야 한다. 어린이가 미녹시딜에 추가로 노출되지 않으면 다모증은 몇 달 내 회복하는 것으로 확인되었다.
6) ~ 13)
<생략>
이전
목록
다음